Eugene Koay, MD, PhD

Dr. Eugene Koay is a physician scientist at The University of Texas MD Anderson Cancer Center, who specializes in radiation therapy for patients with hepatobiliary and pancreatic cancers, and develops applications of the physical sciences to cancer for the purposes of early detection, biomarker development, and therapeutic management. He received a Bachelor of Science in Chemical Engineering from Rice University in 2001. He completed the MD/PhD Program at Baylor College of Medicine/Rice University in 2009, with a PhD in Bioengineering. His residency training was in Radiation Oncology at The University of Texas MD Anderson Cancer Center (2009-2014). He then joined faculty at MD Anderson where he established his clinical and research foci. He leads the Cancer Physics and Engineering Laboratory at MD Anderson.
The lab studies how the physical properties of tumors relate to the biological underpinnings of the disease. Recent work from the lab has shown how radiomics and artificial intelligence-based approaches may lead to clinically-relevant methods to stratify and manage hepatobiliary and pancreatic cancers (Koay et al, JCI, 2014; De et al, Liver Cancer, 2023; Srivastava, Koay et al, Nat Rev Cancer, 2019). Dr. Koay’s lab also collaborates with mathematical modelers to apply physical models of therapeutic delivery (Pascal et al, Proc Nat Acad Sci, 2013; Butner et al, Sci Advances 2020) and tumor growth (Koay et al, Clin Cancer Res, 2018; Zaid et al, Front Oncol, 2020). These studies describe how patient-specific parameters may be used to detect cancer earlier, predict treatment response, and improve cancer outcomes.
Dr. Koay has served on multiple PhD and post-doctoral student committees and currently is the primary mentor to 2 PhD candidates.
The website for the Cancer Physics and Engineering lab is
https://www.mdanderson.org/research/departments-labs-institutes/labs/koay-laboratory.html
For a list of publications, please see
Financial relationships
-
Attribution:SelfType of financial relationship:TravelIneligible company:NanobiotixTopic:Advisory boardDate added:02/12/2025Date updated:02/12/2025Relationship end date:12/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:SiemensTopic:Imaging researchDate added:02/12/2025Date updated:02/12/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:VarianTopic:Clinical researchDate added:02/12/2025Date updated:02/12/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:Clinical researchDate added:02/12/2025Date updated:02/12/2025
-
Attribution:SelfType of financial relationship:PatentIneligible company:KallisioTopic:Licensing of patent for radiation oral stentDate added:02/12/2025Date updated:02/12/2025
-
Attribution:SelfType of financial relationship:Other Business OwnershipIneligible company:Quantum Aurea CapitalTopic:Financial investmentDate added:02/12/2025Date updated:02/12/2025
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.

Facebook
X
LinkedIn
Forward